How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,855 results for

Imiquimod

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1701. Definitive Surgical Treatment of 24 Skin Cancers Not Cured by Prior Imiquimod Therapy: A Case Series. (Abstract)

Definitive Surgical Treatment of 24 Skin Cancers Not Cured by Prior Imiquimod Therapy: A Case Series. 18554288 2009 04 07 2018 12 01 1524-4725 34 9 2008 Sep Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] Dermatol Surg Definitive surgical treatment of 24 skin cancers not cured by prior imiquimod therapy: a case series. 1258-63 10.1111/j.1524-4725.2008.34271.x Murphy Michael E ME The Indiana Skin Cancer Center, Indianapolis, IN 46143, USA (...) . murphymd1@gmail.com Brodland David G DG Zitelli John A JA eng Case Reports Journal Article 2008 06 12 United States Dermatol Surg 9504371 1076-0512 0 Aminoquinolines 0 Antineoplastic Agents P1QW714R7M Imiquimod IM Aged Aminoquinolines therapeutic use Antineoplastic Agents therapeutic use Carcinoma, Basal Cell drug therapy surgery Carcinoma, Squamous Cell drug therapy surgery Female Humans Imiquimod Male Melanoma drug therapy surgery Middle Aged Mohs Surgery Skin Neoplasms drug therapy surgery Treatment

2008 Dermatologic Surgery

1702. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. (Abstract)

Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Patients with metastatic skin disease in malignant melanoma are difficult to treat, with unresectable lesions proving the biggest challenge. We have recently published data showing a significant clinical response in patients with multiple in-transit melanoma metastases treated with a combination of topical imiquimod and intralesional interleukin (...) showed an increase in the ability of cells to produce interferon (IFN)-gamma over the treatment course, with an initial rise in the IFN-gamma/IL-5 ratio in five of six patients.The results of this study provide evidence that, in the majority of patients with in-transit metastases of melanoma, therapy with a combination of topical imiquimod and intralesional IL-2 induces a systemic immunological effect by reversing some of changes noted in patients with malignant disease.

2008 British Journal of Dermatology

1703. Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. (Abstract)

Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. To investigate the activity of 5% Imiquimod cream in the primary treatment of vulva intraepithelial neoplasia (VIN) grade 2/3.Patients with histologically confirmed VIN 2/3 were recruited from regional colposcopy units. A Simon two-stage phase 2 study design was used. Imiquimod cream was applied over the abnormal VIN areas by the patients (...) effects being only minor skin irritation at the application site. Histologic complete response was observed in 21 patients with partial response in another nine patients. The overall response rate was 77% using intention to treat principle. No VIN progression or cancer was diagnosed. At a median follow-up of 16 months in the whole study cohort, eight recurrences (20.5%) were observed. In comparison, the recurrence rate for primary surgically treated patients was 53.5% (p=0.013).Imiquimod cream

2007 Gynecologic Oncology

1704. Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia. (Abstract)

Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia. To investigate CD8+ T cell reactivity to human papillomavirus (HPV) 16 antigens in patients with high-grade vulval intraepithelial neoplasia (VIN) before, during and after treatment with 5% imiquimod cream.CD8-enriched responder cell populations were obtained from 10 patients with high-grade VIN using imiquimod cream as a treatment (...) noticeable in response to peptides derived from the E4 protein. CD8+ T cell reactivity to HPV16 E7 appeared to be dominant amongst women with high-grade VIN. The magnitude and specificity of response had no correlation with clinical response to imiquimod.HPV16 specific CD8+ T cell activity was detected in patients with high-grade VIN. Imiquimod use appeared to increase the magnitude of the response and broaden the specificity of response in some patients. Despite the presence of these CD8+ T cells

2004 Gynecologic Oncology

1705. C/EBPbeta activity and HPV-16 E6/E7 mRNA expression are not altered by imiquimod (ALDARA) in human cervical cancer cells in vitro. (Abstract)

C/EBPbeta activity and HPV-16 E6/E7 mRNA expression are not altered by imiquimod (ALDARA) in human cervical cancer cells in vitro. The purpose of this study was to determine the potential relationship between imiquimod and C/EBPbeta by investigating the extent to which imiquimod could alter C/EBPbeta binding activity to known sequences of the HPV-16 NCR, which could lead to the repression of HPV-16 E6/E7 oncogene expression, possibly impacting a major mechanism by which HPV causes cellular (...) transformation.The effect of imiquimod treatment on C/EBPbeta binding activity to its consensus sequence as well as to two specific regions of the HPV-16 NCR was determined by electromobility shift assay (EMSA) in CaSki cervical cancer cells. HPV-16 E6/E7 gene expression was evaluated by RNase protection assay (RPA) in CaSki and in W12-E cells treated with imiquimod. In addition, C/EBPbeta mRNA expression and protein production in response to imiquimod were evaluated by reverse transcription polymerase chain

2004 Gynecologic Oncology

1706. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. Full Text available with Trip Pro

Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. Imiquimod, an immune response modifier that is used topically to treat different types of skin cancer, induces the production of proinflammatory cytokines that stimulate an antitumor immune response. We assessed characteristics of the imiquimod-induced immune activation in epithelial and lymphoproliferative neoplasias of human skin. We focused on plasmacytoid predendritic cells (...) (PDCs), the primary producer of interferon alpha (IFN-alpha) after imiquimod activation in vitro.We used Affymetrix oligonucleotide arrays to compare gene expression profiles from tumors from 16 patients, 10 with superficial basal cell carcinomas (sBCCs), five with cutaneous T-cell lymphomas (CTCLs), and one with Bowen's disease, before and after topical imiquimod treatment. We used quantitative immunohistochemistry with PDC-specific antibodies against BDCA-2 and CD123 to characterize the PDC

2005 Journal of the National Cancer Institute

1707. Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. (Abstract)

Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Transcutaneous immunization (TCI) using ligands of Toll-like receptors (TLRs) and cytotoxic T-lymphocyte (CTL) epitopes lead to the induction of potent T-cell responses. To characterize the efficacy of TCI-mediated CTL activation, we monitored the frequency and functional activity of specific CTL induced with TCI using the ovalbumin-derived

2007 Clinical Reviews in Allergy & Immunology

1708. Successful treatment of earlobe keloids with imiquimod after tangential shave excision. (Abstract)

Successful treatment of earlobe keloids with imiquimod after tangential shave excision. The treatment of earlobe keloids has historically been suboptimal; characterized by discomfort, poor response, and high rates of recurrence. Keloids are characterized by increased fibroblast activity in the setting of an altered cytokine profile.To investigate whether topical imiquimod 5% cream applied postoperatively after tangential excision can prevent recurrence of earlobe keloids.Four patients (...) with a total of eight large pedunculated earlobe keloids (five of which were recurrent lesions) were treated with debulking by tangential shave excision followed by daily application of imiquimod 5% cream for 6 weeks.At 6 and 12 months post-treatment there was an excellent cosmetic result and no evidence of recurrence in any of the lesions. Patients with keloids that were itchy and painful were completely asymptomatic at the conclusion of the study.In this pilot study, imiquimod 5% cream following

2006 Dermatologic Surgery

1709. Topical imiquimod as an adjuvant to laser removal of mature tattoos in an animal model. (Abstract)

Topical imiquimod as an adjuvant to laser removal of mature tattoos in an animal model. Lasers are a commonly employed method of tattoo removal; however, numerous treatments are often needed and laser treatment may fail to eliminate the tattoo completely. It has been shown in animal studies that topical application of imiquimod cream, alone, fades tattoos. It is suspected that the combination of both imiquimod and laser treatment will result in enhanced tattoo pigment clearance.The objective (...) was to evaluate the efficacy of topical imiquimod cream as an adjuvant to laser removal of mature tattoos.Fourteen albino guinea pigs were tattooed with black ink, then randomly assigned into two groups: one underwent sequential laser treatments with a Q-switched alexandrite laser in conjunction with triweekly applications of 5% imiquimod cream, while the other group underwent laser therapy alone. Subjects were evaluated with clinical photographs and skin biopsies after six laser treatment sessions.The

2007 Dermatologic Surgery

1710. Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. (Abstract)

Treatment of Bowen's disease with topical 5% imiquimod cream: retrospective study. Topical 5% imiquimod cream is an FDA-approved treatment for superficial basal cell carcinomas. It has also been utilized in the treatment of Bowen's disease (squamous cell in situ). The current literature on this subject, however, is scant, and this treatment is only validated by case reports and two small open label studies.The objective was to assess the efficacy of topical 5% imiquimod cream in the treatment (...) of squamous cell in situ in a larger open-label case series. METHODS A retrospective study of 49 patients was performed.Forty-two of the 49 (86%) patients in the study had a complete response with topical imiquimod. The remaining 7 (14%) failed therapy and required additional treatments. The mean follow-up duration was 19 months, with a range of 1 to 44 months.Topical 5% imiquimod cream appears to be clinically beneficial in the treatment of Bowen's disease and should be considered as a treatment option.

2007 Dermatologic Surgery

1711. Rapid improvement of human orf (ecthyma contagiosum) with topical imiquimod cream: report of four complicated cases. (Abstract)

Rapid improvement of human orf (ecthyma contagiosum) with topical imiquimod cream: report of four complicated cases. Orf is a zoonosis caused by an epitheliotropic DNA parapox virus. Human orf is a generally benign, self-limiting condition that usually regresses in 6-8 weeks without specific treatment. However, it may be accompanied by local symptoms including pain, pruritus, lymphangitis and axillary adenitis, or less frequently by systemic symptoms such as fever or malaise. Furthermore (...) , it may be complicated by erythema multiforme, Stevens-Johnson syndrome, erysipelas, generalized mucocutaneous eruption, toxic erythema, eyelid oedema and giant, persistent or recurrent lesions in immunocompromised patients. Imiquimod, a potent topical immune response modifier, enhances both the innate and acquired immunity by stimulation of immune system cells resulting in local antiviral, antitumour and immunoregulatory activity. We present, for the first time, four complicated cases of orf

2005 Journal of Dermatological Treatment

1712. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. (Abstract)

Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. A 58-year-old man was referred to our department for evaluation and treatment of a therapy-resistant pyogenic granuloma on his right third digit. This biopsy-confirmed lesion was unsuccessfully treated with shave excision and base electrocautery on two separate occasions before the patient presented to our clinic. After completing a 14-week course of twice-weekly imiquimod 5% topical application

2006 Journal of Dermatological Treatment

1713. Treatment of mammary and extramammary Paget's skin disease with topical imiquimod. (Abstract)

Treatment of mammary and extramammary Paget's skin disease with topical imiquimod. Paget's disease is an uncommon epidermal cancer, affecting all skin regions wherever apocrine glands are present. It is divided into extramammary (EMPD) and mammary Paget's disease (MPD). It can be confined to the epithelium or may be associated with an underlying adenocarcinoma. The diagnosis is confirmed by skin biopsy and the treatment depends on characteristics of the underlying cancer. Surgery is the first (...) -line treatment. Imiquimod, a topical immunomodulator, approved its efficiency in several skin neoplasms and has been shown as a safe treatment for EMPD. However, it has never been reported for the treatment of MPD.We report on two cases of EMPD and MPD successfully treated with imiquimod 5% cream.This non-surgical method may be considered as a primary treatment when Paget's disease is not associated with an underlying malignancy. The good prognosis with a long-term survival, the anatomic

2006 Journal of Dermatological Treatment

1714. Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod. (Abstract)

Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod. Porokeratosis of Mibelli is a rare genodermatosis characterized by a disorder of keratinization. None of the currently available therapies is effective in all cases and this situation exposes the patient to multiple treatment cycles. We describe the successful use of topical imiquimod 5% cream in the management of porokeratosis of Mibelli of the axillae in a 12-year-old girl. Treatment with imiquimod was effective

2006 Journal of Dermatological Treatment

1715. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation. (Abstract)

Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation. We have treated extensive lentigo maligna in two elderly patients with Imiquimod 5% (Aldara). It was applied 3 times weekly, for 3 to 5 months. Clinical and histological remission was observed over 13 months of follow-up care. Tolerance was good. We suggest that topical imiquimod could be an interesting therapeutic alternative.

2004 Journal of American Academy of Dermatology

1716. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. (Abstract)

Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. Ten patients with superficial infantile hemangiomas were treated with imiquimod 5% cream for up to 16 weeks. Four patients achieved complete clinical resolution, 3 had excellent improvement, one showed moderate improvement, and one patient did not respond to therapy. Imiquimod may be an effective alternative for the treatment of superficial hemangiomas.

2004 Journal of American Academy of Dermatology

1717. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. (Abstract)

Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. Systemic interferon is effective in the treatment of mycosis fungoides (MF). Imiquimod is effective in the treatment of some epidermal neoplasms and induces localized interferon production.To evaluate the safety and efficacy of topical imiquimod 5% cream for the treatment of patch and plaque stage MF.Six patients with stage IA to IIB MF were treated with topical imiquimod 5% cream 3 times per week for 12 weeks (...) imiquimod 5% cream was well tolerated and associated with a histologic and clinical response rate of 50%.

2005 Journal of American Academy of Dermatology

1718. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. (Abstract)

Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. Our case series report is the first documented depiction of the appearance of aphthous ulcers secondary to imiquimod application. This case series presentation discusses the underlying pathophysiology of aphthous ulcer development and imiquimod therapy in terms of the stimulation of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-alpha). The literature review suggests more than just a mere (...) coincidence for the development of aphthous ulcers subsequent to the treatment of actinic cheilitis with imiquimod application.

2005 Journal of American Academy of Dermatology

1719. Imiquimod in the treatment of extensive recurrent lentigo maligna. (Abstract)

Imiquimod in the treatment of extensive recurrent lentigo maligna. We report the case of a 70-year-old white male with an extensive recurrence of lentigo maligna in a skin-transplanted region. He was treated with imiquimod 5% cream topically applied 5 times a week for a total duration of 9 months. Clinically and histologically, a complete clearing of the lesion was observed after treatment. Topical treatment with imiquimod seems to be effective and safe in lentigo maligna.

2005 Journal of American Academy of Dermatology

1720. Imiquimod as an antiaging agent. (Abstract)

Imiquimod as an antiaging agent. Topical imiquimod therapy has proven to be effective for a variety of infectious, neoplastic, and inflammatory dermatologic diseases. Several published reports have validated the benefit of imiquimod therapy for actinic keratoses and superficial melanoma and nonmelanoma skin cancers. There is, however, limited evidence demonstrating the use of topical imiquimod application as an antiaging treatment.We examined the effectiveness of imiquimod 5% cream (...) in the treatment of photoaging by evaluating pretreatment and posttreatment biopsy specimens and documenting the histologic changes.This study represents an extension of an earlier project in our department in which patients with biopsy-proven lesions of lentigo maligna (LM) were recruited from a university dermatology service, a hospital, and referrals from private practitioners for an open-labeled efficacy trial with daily topical application of 5% imiquimod for 3 months. Biopsy of clinically affected skin

2007 Journal of American Academy of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>